In patients with advanced NSCLC and programmed death‐ligand 1 (PD‐L1) expression levels ≥50% and 1%–49%, first‐line monotherapy with immune checkpoint inhibitor is an effective treatment.4, 5, 6. This evidence concerns the gene CD274 and non-small cell lung carcinoma.